Aruni Ghose, Director and Chief Executive Officer at Canprecise AI, Chief Medical Officer at Shiksak, shared a post on LinkedIn:
“Hot off the Press – with an ALL Barts Health NHS Trust Barts Cancer Institute (Queen Mary University of London) Crew!! Prostate Cancer UK, Prostate Cancer Research.
The Kenrick Ng and Jonathan Shamash take on – Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting – published by Springer Nature – thank you Reem Eldebri, Abbas Kassamali.
Optimal Treatment Sequencing in the post-ARTA, post-taxane mCRPC disease entity is clinically uncertain. Available therapeutic options include radioligand therapy (e.g. lutetium-177–PSMA-617), cabazitaxel, PARP inhibitors (particularly for patients with DNA repair gene alterations), second-line ARTAs, further chemotherapy and immunotherapeutic approaches. However, direct head-to-head trials comparing these modalities are sparse. Available data stems from retrospective or subgroup analyses, necessitating a nuanced interpretation of outcomes and limitations.
Beyond efficacy, we emphasize on the critical role of practical and individualized considerations in therapy selection. These include toxicity profiles, patient comorbidities and preferences, biomarker-driven stratification (e.g. BRCA status, PSMA expression, sites of metastases), and health system factors such as drug availability and reimbursement policies, which may significantly influence access to optimal care. We also provide an overview of promising emerging therapies poised to expand the mCRPC treatment landscape – bispecific T cell engagers, androgen receptor degraders, and antibody-drug conjugates.”
Title: Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting
Authors: Kenrick Ng, Birth-Lynn Tyers, Aruni Ghose, Abbas Kassamali, Reem El Debri, Jonathan Shamash
Read The Full Article on Springer Nature
More posts featuring Aruni Ghose on OncoDaily.